There is one clinical trial.
Protocol bacTRL-Spike-1 will be the first-in-human study of bacTRL-Spike, and the first-in-human use of orally delivered bacTRL. Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1A), 3 billion (Group 2A) or 10 billion (Group 3A) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
Description: Adverse events (specifically including incidence of gastrointestinal-associated events) following administration of oral bacTRL-SpikeMeasure: Frequency of Adverse Events Time: Up to12 months post-vaccination
Description: Antibody against SARS-CoV-2 Spike proteinMeasure: Immune response against SARS-CoV-2 Spike protein Time: Baseline (pre-vaccination), and 1, 3 and 12 months post-vaccination
Description: Incidence and clinical phenotype of confirmed and probable COVID-19 infection among vaccinated participants, based on current public health definitionsMeasure: Incidence of COVID-19 infection Time: Up to 12 months post-vaccination
Description: Isolation of viable bacTRL-Spike from stool post-vaccinationMeasure: bacTRL-Spike in stool post-vaccination Time: Days 8, 15, 22, and 1 and 3 months post-vaccination
Description: Collection of biological samples for future studies to understand immunity against SARS-CoV-2.Measure: Immunity against SARS-CoV-2 Time: Up to 12 months post-vaccination
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports